Adiponectin, an adipokine possessing profound insulin-sensitizing and anti-inflammatory properties, is a potent biotherapeutic agent . The trimeric adiponectin subunit assembles into hexameric and functionally important higher molecular weight (HMW) forms, controlled by the endoplasmic reticulum protein 44 (ERp44). Obesity-induced ER stress decreases the HMW form in serum, contributing to the development of insulin resistance and Type 2 diabetes. In this study, a panel of synthetic peptides, designed to target ERp44-adiponectin interactions, were tested for their effects on circulating levels of HMW adiponectin.
Introduction
Adiponectin, a collagenous hormone abundantly and exclusively secreted from adipocytes, exerts a wide range of beneficial functions against obesity-associated pathologies (Tilg and Moschen, 2006; Peake et al., 2008; Yamauchi and Kadowaki, 2008; Liu and Liu, 2014) . In adipocytes, adiponectin is assembled into the trimeric, hexameric and higher molecular weight (HMW) oligomers (Pajvani et al., 2003; Radjainia et al., 2008; Tsao, 2014) , which do not interconvert once released into the circulation (Peake et al., 2005; Schraw et al., 2008) . The various oligomers contain diverse levels of post-translational modifications, such as hydroxylation and glycosylation, and are involved in distinct biological functions (Wang et al., 2006; Wang et al., 2008; Simpson and Whitehead, 2010) . The HMW adiponectin acts to improve insulin sensitivity, decrease blood glucose level and protect against liver injuries (Pajvani et al., 2004; Aso et al., 2006; Hara et al., 2006; Kaser et al., 2008; Aso et al., 2009; Wang et al., 2009) . Decreased circulating HMW adiponectin is implicated in the pathogenesis of medical complications associated with obesity, such as insulin resistance, Type 2 diabetes, hypertension and atherosclerosis (Waki et al., 2003; Bobbert et al., 2005; Basu et al., 2007) . Increase in the ratio of HMW-to-total-adiponectin, rather than the overall adiponectin concentration, is associated with an improved insulin sensitivity in diabetic mice and diabetic patients treated with thiazolidinediones, the PPARγ agonists Long et al., 2010; Abu-Elheiga et al., 2012) . The chaperones in the endoplasmic reticulum (ER), including ER protein 44 (ERp44), Ero1-Lα and DsbA-L, play an important role in the assembly and release of adiponectin oligomers (Qiang et al., 2007; Wang et al., 2007; Zhou et al., 2010; Liu et al., 2012; Hampe et al., 2015) .
The exact mechanisms underlying adiponectin multimerization remain unclear. Previous studies have revealed that ERp44 retains adiponectin in the ER through binding to the highly conserved cysteine residue (Cys 39 ) in the NH 2 -terminal non-collagenous domain of this hormone, in turn controlling its assembly into the HMW form (Qiang et al., 2007; Wang et al., 2007) . ERp44 recognizes fully oxidized hexamers and trimers that cannot assemble into HMW adiponectin and converts them into reduced trimeric precursors (Hampe et al., 2015) . A tryptophan residue (Trp  42 ) located within the variable domain of adiponectin modulates the binding of ERp44 to adiponectin in adipocytes (Radjainia et al., 2012) . It has been shown recently that a histidine-rich region in the COOH-terminal tail of ERp44 is involved in the pH-dependent interactions with its ligands (Watanabe et al., 2017) . Under stress conditions, overload of the unfolded proteins in ER leads to an up-regulation of chaperones including ERp44 (Gregor and Hotamisligil, 2007; Wang et al., 2007; Liu and Liu, 2014) . As a result, a large pool of adiponectin is trapped inside the ER by thiol-mediated linkages between this molecule and ERp44 . The present study investigated whether or not the designed peptide(s) derived from ERp44 ligands were able to facilitate the release of such aberrantly trapped adiponectin in adipocytes. The results demonstrated that, in particular, peptides derived from IgM were effective in modulating ERp44-adiponectin interactions and thus enhancing the secretion of HMW oligomers. These peptides therefore act as potential therapeutic agents to counter obesity-related disorders.
Methods

Production of peptides
Control-WT, Control-C39S, Control-W42A, cell-penetrating peptide (CPP)-WT, CPP-C39S, CPP-W42A, Control-M1, Control-M2, CPP-M1 and CPP-M2 were synthesized manually using Fmoc/ t Bu solid phase synthesis in a fritted glass reaction vessel (Amblard et al., 2006) on amino methyl polystyrene resin (Harris et al., 2011) equipped with the acid labile HMPP linker (Albericio and Barany, 1985) . The N-Fmoc group was deprotected with 20% v/v piperidine in dimethyl formamide (DMF) twice for 10 min, and coupling of individual amino acids was performed with 5.5 equivalents of Fmoc-protected amino acid in DMF (0.2 M), 5 equivalents of O-(benzotriazol-1-yl)-N,N,N 0 , N″-tetramethyluroniumhexafluorophosphate (HBTU) in DMF (0.45 M) and 10 equivalents of diisopropylethylamine in N-methylpyrrolidine (NMP) (2 M) for 30 min. Upon completion of the synthesis, the peptide was released from the resin with concomitant removal of protecting groups by treatment with trifluoroacetic acid /triisopropylsilane/H 2 O/ethane dithiol (94:1:2.5:2.5, v/v/v/v) at room temperature for 3 h. The crude peptide was precipitated with ice cold diethyl ether, isolated by centrifugation, washed with cold diethyl ether, dissolved in 1:1 (v/v) acetonitrile : water containing 0.1% trifluoroacetic acid and lyophilized. Purification using a solvent system of A [0.1% trifluoroacetic acid (TFA) in H 2 O] and B (0.1% TFA in acetonitrile) was performed by semi-prep RP HPLC (Dionex Ultimate 3000 equipped with a 4 channel UV detector) at 210 nm using a Gemini C18 (5 μm; 10 × 250 mm) column (Phenomenex) at 5.0 mL·min À1 flow rate and eluting with an appropriate shallow gradient of increasing concentration of B. Fractions were analysed for purity by HPLC and/or MS, pooled, lyophilized and stored at À20°C. Purified peptides were analysed for purity by analytical HPLC (Dionex Ultimate 3000 equipped with 4 channel UV detector) at 214 nm using a Zorbax Eclipse XDB-C8 (5 μm; 4.6 × 150 mm) column (Agilent, Santa Clara, CA, USA) at 1 mL·min À1 flow rate using a linear gradient of 5-65% over 21 min at approximately 3% B per minute. To remove TFA from the lyophilized peptide, the peptide was dissolved in 10 mM hydrochloride acid (10 mM) at a concentration of 1 mg·mL À1 and again lyophilized. This procedure was repeated three times. LC-MS was performed using an Agilent 1100 Compact HPLC equipped with a single wavelength UV detector at 214 nm with an in-line Hewlett Packard (Palo Alto, CA, USA) 1100MSD mass spectrometer using ESI in the positive mode. The solvent system used was A (0.1% formic acid in H 2 O) and B (0.1% formic acid in acetonitrile). An Agilent Zorbax 300SB-C3 3.5 μ; 3.0 × 150 mm column was used with a linear gradient of 5 to 65% B over 21 min at 0.3 mL·min
À1
. 
Control
Production of recombinant murine ERp44
The cDNA encoding murine ERp44 without the signal sequence was amplified by PCR and cloned into the pET28b vector at the NheI and XhoI sites. Recombinant ERp44 was overexpressed in Escherichia coli and purified as described (Hampe et al., 2015) . To separate ERp44 monomers and dimers, purified protein was loaded onto a Superdex-200 10/300 GL column (GE Healthcare, Piscataway, NJ, USA; pre-equilibrated with 20 mM MES, 150 mM NaCl, pH 6.5).
The fractions containing monomeric ERp44 as the main component were pooled, confirmed by non-reducing SDS-PAGE and used for subsequent experiments.
Electrospray ionization mass spectrometry
Mass spectrometry was used to quantify the amount of disulfide linkage between ERp44 and the various peptides. For this purpose, ERp44 (43 μM) was incubated with 10-fold excess (430 μM) of the individual peptides (Control-WT, CPP-WT, Control-W42A, CPP-W42A, Control-C39S, CPP-C39S, Control-M1, CPP-M1, Control-M2 and CPP-M2). All samples were incubated for 4 days in 20 mM MES, 150 mM NaCl at pH 6.5 and subsequently subjected to mass spectrometric analyses. For LC-MS analysis, samples were diluted in 0.1% formic acid, and 10 μL was injected onto a 0.32 × 100 mm, 3 μm Discovery Bio Wide pore C5 column (Supelco, Bellefonte, PA, USA) and separated using the following gradient at a flow rate of 6 mL·min À1 : 0-4 min 10% B; 24 min 70% B, 27 min 97% B, 30 min 97% B, 32 min 10% B and 35 min 10% B where A was 0.1% formic acid in water and B was 0.1% formic acid in acetonitrile.
The column eluate was ionized in the electrospray source of a QSTAR-XL quadrupole time-of-flight mass spectrometer (Applied Biosystems, Foster City, CA, USA). A TOF-MS scan from 400 to 1600 m/z was performed. The resulting data were de-convoluted into protein molecular masses using the Bayesian Protein Reconstruct Tool within Analyst QS 1.1 (Applied Biosystems).
Cell culture
The 3T3-L1 cells (ATCC #CL-173, Manassas, VA, USA) were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin-fungisone at 37°C and under 5% CO 2 95% humidified air. For differentiation, the confluent 3T3-L1 cultures were supplemented with 10 μg·mL À1 insulin, 0.25 μM dexamethasone and 0.5 mM isobutylmethylxanthine for 2 days, followed by the incubation with 10 μg·mL
À1
insulin in the culture medium for another 2 days. Subsequently, cells were incubated in DMEM with 10% FBS that was changed every 2 days. Peptide treatment (200 nM in FBS-free medium) was performed in fully differentiated 3T3-L1 adipocyte cultures. After incubation for 24 h, cell lysates and the conditioned medium were collected for subsequent analyses.
Immunoprecipitation and Western blotting
Cells or adipose tissues were washed with phosphate buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.47 mM KH 2 PO 4 , pH 7.4) and then solubilized in lysis buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM NaF, 1% sodium deoxycholate, 1% Nonidet P-40, 1% Triton X-100 plus protease inhibitor mixtures). Equal amounts of lysates (100 μg) were precleared with protein G (Thermo Fisher Scientific, Waltham, MA, USA) and incubated overnight with specific antibodies at 4°C with shaking. After incubating with protein G for another 4 h, the immune complexes were precipitated by low-speed centrifugation, washed three times with lysis buffer and eluted in SDS-PAGE sample buffer (50 mM Tris-HCl pH 6.8, 1% SDS, 5% glycerol, 3% β-mercaptomethanol, 0.01% bromophenol blue) or 0.1 M glycine HCl (pH 3.0) and then diluted with non-reducing sample buffer (1% SDS, 5% glycerol, 10 mM Tris-HCl pH 6.8) for analysing adiponectin monomers and oligomers by Western blotting. Cell lysates, media or serum samples were incubated with non-reducing sample buffer at room temperature for 10 min and then separated by 4-20% gradient SDS-PAGE. After transferring to PVDF membranes, immunoblotting was performed using an in-house antibody against murine adiponectin developed by Antibody and Immunoassay Services, HKU (http://www.pharma.hku.hk/sweb/antibody/ PolyclonalAntibodyCont.php?polyclonal_no=600005), or antibodies against ERp44 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), DsbA-L (Abcam, Cambridge, MA, USA). Protein bands were quantified by ImageJ and intensities were compared. All experiments were repeated at least six times.
Quantitative reverse-transcription polymerase chain reaction (QPCR)
Total RNA was isolated from adipose tissues using TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed by Superscript III reverse transcription system (Invitrogen). QPCR was performed using SYBR Green PCR Master Mix (Qiagen, Hamburg, Germany) on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems).
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Genes involved in regulating ER stress response, including those for ER carbohydrate-binding protein (EDEM), 78 kDa glucose-regulated protein (GRP78), protein disulfide isomerase (PDI), endoplasmic reticulum-localized DnaJ 4 (ERdj4), activating transcription factor 4 (ATF4) and CCAATenhancer-binding protein homologous protein (CHOP) and adiponectin (Adipoq) were quantified using primers listed in Supporting Information Table S1 . Data were calculated as relative expression of transcripts normalized to β-actin.
Animal studies
All animal care and experimental protocols complied with the institutional guidelines for the care and use of laboratory animals and were approved by the Committee on the Use of Live Animals for Teaching and Research of the University of Hong Kong. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Male mice of the C57BL/6J background were housed in a room under controlled temperature (23 ± 1°C) with 12 h light-dark cycles and free access to water and food. )/22.5 for comparison as described (Xu et al., 2013) . All results were compared between mice treated with Control peptides and CPPs.
Data analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data are presented as mean ± SEM. The density of protein bands in Western blots was quantified using ImageJ 1.45 (NIH, Bethesda, MD, USA) software. Statistical calculations were performed using the Statistical Package for the Social Sciences version 11.5 (SPSS, Inc., Chicago, IL, USA). For multiple comparisons, the differences were analysed by one-way ANOVA, followed by Dunnett's test. Quantification of the differences in other comparisons was carried out by an unpaired two-tailed Student's t-test. In all cases, statistically significant differences were accepted when P values were less than 0.05. All results were derived from at least six sets of independent experiments unless otherwise specified.
Materials
For peptide synthesis, all solvents and reagents were used as supplied. HBTU, O-(7-azabenzotriazol-1-yl)-N,N,N 0 ,N 0 -tetramethyluroniumhexafluorophosphate and stritylmercaptopropionic acid were purchased from GL Biochem (Shanghai, China). Dimethylformamide (DMF) (AR grade) and acetonitrile (HPLC grade) were purchased from Scharlau (Barcelona, Spain) . N, N 0 -diisopropylethylamine, piperidine, piperazine, ethanedithiol, diisopropylcarbodiimide, triisopropylsilane, dimethylsulfide, tert-butylammonium iodide and phenylacetamidomethyl linker were purchased from Sigma-Aldrich (St. Louis, MO, USA), and NMP was purchased from Fluka (Buchs, Switzerland). TFA was purchased from Halocarbon (River Edge, NJ, USA). 1-Hydroxybenzotriazole hydrate was purchased from Advanced Chemtech (Louisville, KY, USA). Anhydrous hydrogen fluoride was obtained from Matheson Trigas (Basking Ridge, NJ, USA). Aminomethyl polystyrene resin was synthesized 'in house' as described (Harris et al., 2011) . Aminomethyl ChemMatrix resin was obtained from PCAS Biomatrix (Quebec, Canada). Fmoc-amino acids were purchased from GL Biochem. The cDNA encoding mouse ERp44 was purchased from OriGene Technologies (Rockville, USA). Restriction enzymes were from Roche Diagnostics N.Z., Ltd (New Zealand). DNA Oligonuclotides were from Integrated DNA Technologies Pte. Ltd. (Singapore). Other chemicals were from Sigma-Aldrich. All reagents for cell culture were purchased from Invitrogen Corporation (Grand Island, NY, USA). Consumables for Western blotting including PVDF membrane, enhanced chemiluminescence (ECL) plus detection kit and ECL advance detection kit were purchased from GE Healthcare. Medical X-ray film was purchased from Fuji (Tokyo, Japan).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2015/16 .
Results
Design and synthesis of peptide ligands
Two sets of peptides (Table 1) were designed and synthesized for assessing their ability to counteract the impaired adiponectin assembly and secretion under obesity-induced ER stress conditions (Ozcan et al., 2004; Kawasaki et al., 2012) . The first set was based upon the known binding site of IgM antibodies to ERp44. IgM antibodies have been extensively examined with regard to its assembly into distinct polymers in the ER and the involvement of ERp44 in this process (Anelli et al., 2015) . A highly conserved 18-amino acid segment located at the COOH-terminus of IgM μ chain contains the ERp44 binding site (Anelli et al., 2007) . In particular, the Cys 575 in a GTCY motif, controls the assembly of Designed peptides counter obesity-related disorders BJP IgM (Anelli et al., 2015) . Thus, two peptides derived from the COOH-terminal of IgM were synthesized including a fouramino acid peptide GTCY (Control-M1) and a seven-amino acid fragment DTGGTCY (Control-M2) ( Table 1) . To ensure the delivery of these peptides into the ER, the CPP (YGRKKRRQRRR) derived from the COOH-terminus of trans-activating transcriptional activator of human immunodeficiency virus (Pujals et al., 2006) was fused at the NH 2 -terminus of M1 and M2 to generate two peptides called CPP-M1 and CPP-M2 respectively (Table 1) . The second set of peptides was designed based on a highly conserved region within the variable domain of adiponectin, which interacts with ERp44 via a disulfide linkage (Hampe et al., 2015 trol-C39S) and alanine (Control-W42A), respectively, were also prepared ( Figure 1B ). These mutants were included because the Cys 39 in adiponectin is essential for the formation of the covalent linkage between ERp44 and adiponectin (Hampe et al., 2015) and Trp 42 was shown to regulate binding of ERp44 to adiponectin and oligomeric assembly of adiponectin (Radjainia et al., 2012) . The adiponectinderived peptides were synthesized with CPP tagged at the NH 2 -termini to produce CPP-WT, CPP-C39S and CPP-W42A (Table 1) . For all subsequent experiments, Control peptides were included together with CPPs for treatment and comparisons. For the sake of simplicity, hereafter, we refer to the various fusion peptides as CPPs. The in vitro binding of IgM-and adiponectin-derived peptides to ERp44 was assessed by co-incubation and electron spray ionization mass spectrometry (ESI-MS) analyses (Hampe et al., 2015) . Individual peptides were incubated with the recombinant murine ERp44 at a ratio of 10:1 for 4 days at 4°C. The formation of ERp44-Control peptides or ERp44-CPP-peptide complexes was confirmed by ESI-MS (Figure 1) . The binding of Control-M2 peptide to ERp44 was significantly lower than that of M1 peptide (Figure 1 ). Both M1 and M2 peptides fused to CPP sequences showed decreased propensity to complex with ERp44 (Figure 1) . The CPP-W42A peptide showed an enhanced complex formation with ERp44 when compared to CPP-WT. CPP-C39S failed to show any complex formation (Figure 1 ).
CPPs modulate ERp44-adiponectin interactions in 3T3-L1 adipocytes
The ability of Control-and CPP-peptides to perturb ERp44-adiponectin interactions and/or adiponectin production was evaluated in 3T3-L1 adipocyte cultures. Cells were incubated with individual peptides in serum-free medium for 24 h. At the end of the treatment, both cell lysates and conditioned media were collected for measuring the total Amino acid sequence alignment of the tail fragment of Ig-μ and Ig-α chains and between the IgM-derived peptides (with or without the N-terminal CPP sequences) and. The conserved penultimate cysteine is highlighted in red and the conserved residues at the C-terminal end coloured in green. Amino acid sequence comparison between the adiponectin-derived peptides (with or without the N-terminal CPP sequences) and the variable domain of human and murine adiponectin.
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Figure 1
Disulfide-bonded complex formed between ERp44 and designed peptides as analysed by ESI-MS. Experiments to assay the binding of ERp44 and designed CPPs in vitro. For this purpose, recombinant mouse ERp44 (43 μM) was incubated with 10-fold excess (430 μM) of each peptide [M1 (A), CPP-M1 (B), M2 (C), CPP-M2 (D), WT (E), CPP-WT (F), W42A (G), CPP-W42A (H), C39S (I) and CPP-C39S (J)] for 4 days, and the mixture was subsequently analysed by ESI-MS to quantify the amount of disulfide-linked complex formed. Each of the spectra contains two sets of peaks, one at 46 074 atomic mass units (amu) representing free ERp44 and a second representing the disulfide-linked ERp44-peptide complex as indicated. The amounts of the complexed and uncomplexed species were estimated based on the area under the peak. The ratio of complex/free ERp44 was used for comparison between the different experiments. For M2, more complex was detected than for M1. The amount of complex was reduced for both CPP-M1 and CPP-M2. WT and WT-CPP formed more complex when compared to the W42A and W42A-CPP respectively. No complex was found in the case of C39S and CPP-C39S.
Designed peptides counter obesity-related disorders BJP adiponectin levels. When compared to the corresponding samples incubated with Control peptides, treatment with CPP-M1 or CPP-M2 significantly increased the total amount of adiponectin secreted in the media (by about 50%) but decreased the intracellular adiponectin levels (Figure 2A ). On the other hand, the total amount of adiponectin in the conditioned media was significantly reduced after incubation with CPP-WT or CPP-W42A ( Figure 2B ). Concomitantly, CPP-WT or CPP-W42A treatment significantly increased the cellular levels of adiponectin. Non-reducing SDS-PAGE was performed to analyse the oligomeric distribution of adiponectin in the conditioned media. The results demonstrated that all three (trimer, hexamer and HMW) forms of adiponectin were significantly elevated after treatment with CPP-M1 or CPP-M2 ( Figure 2C ), whereas the amounts of trimeric and HMW adiponectin were significantly reduced in the media collected from CPP-WT-or CPP-W42A-treated cells ( Figure 2D ). CPP-C39S did not affect the oligomeric distribution of adiponectin in the conditioned media ( Figure 2B, D) . The mRNA levels of Adipoq were not altered by treatment with any of the peptides ( Figure 2E ). IgMderived CPPs significantly increased the amount of HMW adiponectin but decreased a sub-population of the hexametric adiponectin in the cell lysates when compared to those treated with IgM-derived Control peptides (Figure 3  A) . In cells treated with CPP-WT or CPP-W42A, the oligomeric composition was shifted towards the trimer ( Figure 3B ).
CPP-C39S did not cause any alteration in the intracellular distribution of the adiponectin oligomers ( Figure 3B ). Co-immunoprecipitation was performed to determine the amount of adiponectin associated with ERp44. The results demonstrated that both CPP-WT and CPP-W42A reduced total ERp44-adiponectin interactions, whereas CPP-C39S had no effect. The inhibition of ERp44-adiponectin interactions by CPP-M1 and CPP-M2 appeared to be less pronounced when compared to adiponectin-derived CPPs ( Figure 3C ). When the precipitated immune complexes were separated by non-reducing SDS-PAGE, samples treated with CPP-M1 or CPP-M2 contained a molecular complex running at a lower molecular weight than the trimer ( Figure 3C ).
IgM-derived CPPs enhance HMWadiponectin levels in obese mice
Obesity causes ER stress, a central feature of insulin resistance and type 2 diabetes (Ozcan et al., 2004; Kawasaki et al., 2012) .
Figure 2
IgM-and adiponectin-derived CPPs modulated adiponectin production from 3T3-L1 adipocytes. Murine 3T3-L1 adipocytes cultured in serumfree medium were treated with (A) IgM-or (B) adiponectin-derived peptides (200 nM each). After 24 h of incubation, both the cell lysates and the conditioned media were collected to measure the adiponectin content using an in-house ELISA for adiponectin. Non-reducing SDS-PAGE was performed for determining the adiponectin oligomeric distribution in the conditioned media collected from 3T3-L1 adipocytes treated with (C) IgM-or (D) adiponectin-derived peptides. The same volume (5 μL) of media was loaded for comparison. The intensities of the protein bands were quantified by Image J software. Results were normalized to the corresponding control peptides and presented as fold changes. (E) mRNA expression of adiponectin in peptide-treated cell was evaluated by quantitative PCR and presented as fold change. *P < 0.05, significantly different from the corresponding non-CPP control peptide in each group (n = 6).
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In order to determine the time at which obese mice should be given the peptide treatment, markers of ER stress were assessed in adipose tissues of mice fed with HFD for different periods. The results demonstrated that, when compared to mice given STC, the expressions of all of the six ER stress marker genes were progressively up-regulated by the HFD. At the age of 12 weeks (i.e. after 8 weeks of HFD), the gene expressions of five ER stress markers (EDEM, GRP78, ERdj4, ATF4 and PDI) were more than two-fold higher in adipose tissues of the HFD group than in those from the STC group (Supporting Information Figure S1A ). After 12 weeks of HFD (i.e. at the age of 16 weeks), all six ER stress markers were augmented by at least twofold when compared to samples from mice given STC. HFD treatment up-regulated ERp44 but down-regulated DsbA-L expressions (Supporting Information Figure S1B ).
Therefore,we used mice at the age of 16 weeks with 12 weeks of HFD exposure for our first study of acute treatment with IgM-or adiponectin-derived peptides (a single i.p. injection of 10 mg·kg À1 peptide). The serum was collected 24 h after injection. The circulating concentrations of adiponectin were significantly increased in mice treated with CPP-M1 or CPP-M2 but decreased in those treated with CPP-WT or CPP-W42A, compared with the corresponding control groups ( Figure 4A ). CPP-C39S did not change the total amount of adiponectin in serum samples. Oligomeric composition analysis in mouse serum samples by non-reducing SDS-PAGE revealed that the increase in the HMW form of adiponectin was more pronounced in mouse treated with CPP-M1 or CPP-M2 ( Figure 4B ). On the other hand, the HMW adiponectin was significantly decreased in serum samples of mice treated with CPP-WT or CPP-W42A (Supporting Information Figure S2 ). The interactions between adiponectin and ERp44 were subsequently analysed using extracts of adipose tissues. The results demonstrated that adiponectinderived CPPs (except C39S) significantly decreased the amount of adiponectin bound to ERp44 ( Figure 4C ). In samples from those treated with IgM-derived CPPs, a species with a lower molecular weight than adiponectin trimers was detected to be interacting with ERp44 ( Figure 4C ).
Chronic treatment with IgM-derived CPPs improves insulin sensitivity and energy homeostasis in obese mice
IgM-derived Control peptides or CPPs were chronically administered (i.p., 5 mg·kg À1 ·day À1 for 4 weeks) to mice fed either with STC or HFD, starting from the age of 12 weeks. Body weights were monitored on a daily basis. The gain of body weight was higher in mice under HFD than those of STC groups. However, this was not reduced by treatment with IgM-derived peptides (Supporting Information Figure S3 ). The fasting body weights were comparable between Control peptides and CPPs in either the STC or HFD groups
Figure 3
IgM-and adiponectin-derived CPPs modulated adiponectin production by interfering with the ERp44-adiponectin interactions in 3T3-L1 adipocytes. Cell lysates were collected from 3T3-L1 adipocytes after 24 h treatment with (A) IgM-or (B) adiponectin-derived peptides. Samples containing the same amount of adiponectin (20 ng) were separated by non-reducing SDS-PAGE (top) to analyse different oligomers. Adiponectin monomer was detected by reducing SDS-PAGE to confirm the equal amount of loading. The relative intensity of adiponectin oligomers was analysed by Image J software and presented as fold changes for comparison (bottom). (C) Co-immunoprecipitation was performed in 3T3-L1 adipocytes lysate treated with adiponectin-or IgM-derived peptides. The immune complex was precipitated from the cell lysates by a specific antibody against ERp44. The amount of adiponectin oligomers bound to ERp44 was analysed by non-reducing SDS-PAGE (top), and the total bound adiponectin was evaluated by reducing SDS-PAGE (middle). The relative intensity of total adiponectin level was analysed by Image J software and normalized by input. The total adiponectin-ERp44 interaction was presented as fold changes for comparison (bottom). *P < 0.05, significantly different from the corresponding non-CPP control peptide in each group (n = 6).
( Figure 5A ). After 4 weeks of treatment, mice treated with CPP-M1 exhibited a significantly decreased body fat mass than those of Control-M1 under HFD ( Figure 5B ). The body fat mass was not significantly different in mice under STC, regardless of the treatment groups. Both CPP-M1 and CPP-M2 significantly blocked HFD-induced hyperglycaemia and insulin resistance, as demonstrated by the fasting glucose levels and the calculated HOMA-IR ( Figure 5C, D) . At the end of the 4 week treatment, mice were fasted for 16 h and killed to collect serum and tissue samples for analyses. The circulating concentrations of adiponectin were significantly decreased by HFD when compared with mice given STC ( Figure 6A ). Treatment with either CPP-M1 or CPP-M2 prevented the reduction of adiponectin concentrations in serum ( Figure 6A ). When compared to mice given STC, HFD augmented the circulating triglyceride and cholesterol levels, which were significantly reduced by treatment with either CPP-M1 or CPP-M2 ( Figure 6B, C) . The peptides did not affect the triglycerides and cholesterol levels in serum from mice given STC ( Figure 6B, C) . HFD significantly increased the amount of triglyceride accumulated in the liver tissues. Chronic treatment with CPP-M1 or CPP-M2 attenuated the lipid accumulation in livers of mice given HFD ( Figure 6D ).
Discussion
Under normal physiological conditions, adiponectin is circulating at the level of μg per mL, a concentration much higher than many other hormones (Ge et al., 2010) . Reduced expression and/or secretion of adiponectin is, at least in part, responsible for the pathogenesis of the cardiometabolic syndrome associated with obesity (Ziemke and Mantzoros, 2010) . Therefore, restoration of adiponectin levels represents a promising therapeutic strategy for obese patients with insulin resistance and Type2 diabetes Liu and Liu, 2014) . In animals, administration of adiponectin increased glucose uptake and fat oxidation in muscle, decreased hepatic gluconeogenesis and improved insulin sensitivity Ziemke and Mantzoros, 2010) . However, large-scale production of the polymorphic and bioactive adiponectin, especially the HMW form, remains challenging. To circumvent this problem, regulation or manipulation of Figure 4 IgM-derived CPPs increased HMW adiponectin levels in obese mice. C57/BL6 mice fed for 8 weeks with a HFD and treated with IgM-or adiponectin-derived peptides (10 mg·kg À1 , single i.p. injection). (A) Serum samples collected at time 0 or 24 h after peptide injection were used for determining the concentrations of circulating adiponectin by an in-house ELISA as described. (B) Serum samples (1 μL) collected from mice treated with IgM-derived peptides was used for analysing adiponectin oligomeric distribution by non-reducing SDS-PAGE (left). The relative intensity of the HMW adiponectin was quantified by Image J software. Results were normalized to the corresponding control peptides collected at time 0 and presented as fold changes (right). (C) Co-immunoprecipitation experiment was performed using the adipose tissue lysates prepared from mice treated with adiponectin-or IgM-derived peptides. The immune complexes precipitated by the specific antibody against ERp44 were subjected to non-reducing SDS-PAGE for analysing adiponectin oligomers binding to ERp44 (top) or reducing SDS-PAGE for probing the total amount of bound adiponectin (middle). The relative intensity of total adiponectin was analysed by Image J software and normalized by input. The total adiponectin-ERp44 interaction was presented as fold changes for comparison (bottom). *P < 0.05, significantly different from the corresponding control peptide groups (n = 6).
endogenous pathways controlling the efficient expression, assembly, secretion or release of adiponectin protein represents a promising avenue for managing obesity-associated abnormalities, such as hyperlipidaemia, insulin resistance, Type 2 diabetes and vascular inflammation (Liu et al., 2012; Liu and Liu, 2014) . ERp44 is critically involved in the assembly and release of adiponectin oligomers (Anelli et al., 2015) . Fully oxidized adiponectin hexamers and trimers, which cannot further assemble into HMW adiponectin, are retained in the ERGolgi intermediate compartment (ERGIC) via thiol-mediated mechanisms (Hampe et al., 2015) . In particular, ERp44 binds to the highly oxidized hexameric adiponectin and then the complex is sent back to the ER, where the release of trimeric adiponectin is facilitated by Ero1-Lα for subsequent formation of HMW oligomers. Under conditions of obesity, ER stress in adipocytes leads to impaired assembly and release of adiponectin oligomers (Zhou et al., 2010; Liu and Liu, 2014) . In the present study, synthetic peptides were used to compete with endogenous adiponectin in adipocytes to augment the release of this hormone from ERp44 (Figure 7 ). To this end, a panel of rationally designed peptides derived from the variable domain of adiponectin and the COOHterminus of IgM were tested. By conjugation with a CPP sequence, the fusion peptides gained access into the cells to potentially interfere with the interaction between ERp44 and adiponectin in adipocytes. This targeted approach turned out to be very effective in modulating the ERp44-adiponectin interactions, as well as the assembly and/or release of the bound adiponectin. In particular, the peptides modulated the assembly and/or release of adiponectin in obese but not lean mice, supporting their actions against ER stress in adipose tissues. Importantly, the IgM-derived CPPs significantly enhanced the production of HMW adiponectin and in turn improved insulin sensitivity and decreased circulating lipid levels in obese mice. Compared to the effects of the thiazolidinediones, the current approach does not change the gene expression levels of adiponectin and ER chaperones, thus avoiding potential deleterious side effects (Wright et al., 2014) .
The effects on the assembly and secretion of adiponectin oligomers were noticeably different between the two groups of peptides that we tested. Treatment with the adiponectin-derived peptides, CPP-WT and CPP-W42A (but not CPP-C39S) led to significant inhibition in the binding between ERp44 and adiponectin in cell culture and adipocytes, as reflected by the lesser amounts of both trimeric and hexameric adiponectin bound to ERp44. This interference caused a shift in oligomer distribution in both adipocyte cells and in the cell media. Thus, in the cell lysate, the amounts of hexameric and HMW adiponectin were reduced, whereas the amount of trimer was increased. Also, in the cell medium, the amounts of both the trimeric and HMW forms decreased. Taken together, these observations suggest that the inhibition of the interaction between adiponectin and ERp44 by these adiponectin-derived CPPs elicit different responses for
Figure 5
Chronic treatment with IgM-derived CPPs enhanced systemic insulin sensitivity in obese mice. Mice given STC or HFD were treated with Control peptides or CPPs (5 mg·kg À1 ·day À1 ; i.p. injection) for 4 weeks, starting from the age of 12 weeks. At 0, 2 and 4 weeks of treatment, mice were subjected to overnight starvation (food removal for 16 h). The fasting body weight was recorded from for comparison (A). The total body fat composition was determined by the minispec Body Composition Analyzer and presented as percentage of total body fat mass for comparison (B). At the end of the 4 week treatment, the fasting blood glucose was measured for comparison (C). Meanwhile, the fasting insulin level was determined and the HOMA-IR value calculated for comparison (D). *P < 0.05, significantly different from the corresponding non-CPP control peptide groups. #P < 0.05, significantly different from the corresponding STC group (n = 6).
Designed peptides counter obesity-related disorders BJP the hexameric and the trimeric forms. It appears that the interaction of ERp44 with adiponectin is modulated in a way that leads to an increased release of hexamer into the medium and/or conversion of the hexameric form to the trimeric form. This observation is in line with our previously reported results (Hampe et al., 2015) that ERp44 retains these two oligomers in cellular compartments and converts a portion of the hexameric species into the trimers. On the other hand, the intervention in the binding of ERp44 with trimeric adiponectin appears to arrest secretion resulting in an accumulation of this form within the cells. Although the cellular events that cause these are yet to be revealed, what is clear is that the manipulation of ERp44-adiponectin interaction by the adiponectin-derived CPPs disturbs the process of both the assembly and secretion of the HMW form. This is due to the fact that lesser amounts of HMW are formed within adipocytes, causing decreased amount of HMW to be secreted into the medium. In contrast to adiponectin-derived CPPs, IgM-derived CPPs modulate the interactions between adiponectin and ERp44 to a much lesser extent. This weak modulation leads to an increase in the concentration of HMW in the cells at the expense of the hexamers. In fact, close examination of the Western blot of the intracellular adiponectin sample reveals that the hexameric form consists of at least two different species,only one of which was affected by the peptide treatment. This suggests that the various populations of hexamers are isoforms that differ in their oxidative state. As indicated in our earlier study (Hampe et al., 2015) , ERp44 specifically recognizes the fully oxidized fraction of hexamer species and converts these into reduced trimers. IgM-derived CPPs appear to accelerate the rate of conversion into trimers. However, opposite to the observation for their adiponectin-derived counterparts, IgM derived peptides do not cause an accumulation of the trimeric species in the cells. Rather, it appears that the generated trimers are converted into HMW. As a consequence, we observed an increase in HMW adiponectin within adipocyte cells, and this higher abundance of HMW also leads to an increased secretion of this oligomer.
These differences in treatment outcomes might be due to the differences in the binding affinity of CPPs to ERp44 in the two cases, as indicated by the ESI-MS studies (Figure 1 ) and co-IP experiments ( Figures 3C and 4C) . The covalent linkages between adiponectin and ERp44 appear to be tight , whereas those of IgM and ERp44 undergo rapid cycles of binding and release (Cortini and Sitia, 2010) . The transient binding of IgM-derived peptides to ERp44 potentially enhances the turnover rate of the ERp44 binding and release cycle for adiponectin. On the other hand, the strong binding of ERp44 to adiponectin-derived CPPs appears to release adiponectin from ERp44 but inhibits the cycle of binding and release of ERp44 to endogenous adiponectin.
ERp44 and Ero1-Lα have been demonstrated to modulate adiponectin secretion in a tightly controlled fashion (Qiang et al., 2007; Wang et al., 2008) , whereas ERp44 acts in synergy with ERGIC-53 to control IgM assembly (Cortini and Figure 6 Chronic treatment with IgM-derived CPPs improved lipid metabolism in obese mice. Control peptides or CPPs were administered into mice fed with either STC or HFD as in Figure 5 . After 4 weeks of treatment, mice were starved for 16 h and then killed to collect the serum and tissue samples. Circulating adiponectin levels were measured in serum samples by an in-house ELISA for comparison (A). The serum concentrations of triglyceride (B) and total cholesterol (C) were also measured for comparison. In addition, the hepatic triglyceride contents were examined and normalized against the tissue weight for comparison (D). *P < 0.05, significantly different from the corresponding non-CPP Control peptide groups; #P < 0.05, significantly different from the corresponding STC group (n = 6). BJP L Hampe et al. Sitia, 2010) . Therefore, binding of adiponectin-derived peptides may direct the ERp44 peptide complex towards a distinct pathway, and the IgM-derived peptide ERp44 complex may participate in a second independent cascade of events in the ER resulting in different effects on adiponectin assembly and release. It is possible that such a scenario leads to the additional band observed in the co-IP experiment after treatment with IgM-derived CPPs ( Figures 3C and  4C) , which represents an, hitherto, unknown intermediate in the reassembly process of adiponectin. This observation requires further examination. A third factor may be that the assembly of adiponectin and oligomerization of IgM occurs in different sub-compartments of the ER (Cortini and Sitia, 2010; Anelli et al., 2015) . Thus, the two groups of peptides may interfere with ERp44 action in different places of the ER leading to different nature of modulation in adiponectin assembly.
In this study, we have demonstrated that long-term treatment with IgM-derived peptides significantly enhanced circulating adiponectin levels in obese mice, which contributed to the reduction in circulating lipid levels and improvement in insulin sensitivity. The metabolic profile of mice fed with STC was not affected by the treatment with CPPs. These results establish the therapeutic potential of directly targeting the ERp44-adiponectin interactions with CPPs to counteract impaired adiponectin multimerization caused by dysregulated ER chaperone expression and function during obesity. These peptides can therefore act as effective reagents for the treatment of obese patients with insulin resistance and Type 2 diabetes. The small peptides derived from ERp44 ligand proteins are able to attenuate ERp44-mediated retention of adiponectin in a mode of action distinct from that for the thiazolidinediones. CPP binding triggers adiponectin release from ERp44 and allows assembly of adiponectin into its HMW form and subsequent secretion into circulation. Moreover, this targeted approach can be employed in a dose-or time-dependent manner to effectively control the release of HMW adiponectin into the circulation from adipose tissue. This unique approach opens up a novel avenue for the treatment of obesity-associated diseases.
adiponectin oligomers by non-reducing SDS-PAGE. The intensity of HMW was quantified by Image J software and presented as relative fold changes normalized to the control peptide group (at time zero). *, P < 0.05 compared with the corresponding Control samples (n = 6). Figure S3 Comparison of body weight gain in mice treated with IgM-derived peptides. At the age of 12-weeks, mice fed with either standard chow (STC) or high fat diet (HFD) were subjected to chronic (four-week) treatment with IgM-derived Control or CPP peptides (5 mg·kg À1 ·day À1 by intraperitoneal injection). Non-fasting body weights were monitored at 10 am on a daily basis. The body weight gain is presented for the whole period of peptide treatment for comparison. 
